Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + dexamethasone + doxorubicin hydrochloride liposome
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This is a three-drug combination regimen used primarily for multiple myeloma treatment. The combination leverages synergistic effects between the proteasome inhibitor bortezomib, the corticosteroid dexamethasone, and the anthracycline chemotherapy agent doxorubicin in its liposomal formulation. Bortezomib inhibits the 26S proteasome, disrupting protein degradation and causing cancer cell death. Dexamethasone provides anti-inflammatory and immunosuppressive effects. Pegylated liposomal doxorubicin delivers the cytotoxic agent doxorubicin with improved pharmacokinetics and reduced cardiotoxicity compared to conventional doxorubicin.
- Brand names
- Velcade (bortezomib) + Doxil (doxorubicin hydrochloride liposome) + dexamethasone
- Other names
- Bortezomib, pegylated liposomal doxorubicin and dexamethasone combination
02
Targets
GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on bortezomib + dexamethasone + doxorubicin hydrochloride liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + dexamethasone + doxorubicin hydrochloride liposome.